Formula of antibacterial liquid for treating human papilloma virus (HPV) infection

Abstract

The invention provides an antibacterial liquid formula for treating human papilloma virus (HPV) infection, and relates to the technical field of traditional Chinese medicine pharmacy, the antibacterial liquid formula comprises coptis chinensis, oriental wormwood, radix sophorae flavescentis, fructus cnidii, radix paeoniae rubra, angelica sinensis, radix rehmanniae preparata, lithospermum erythrorhizon, golden cypress, silver ions and brucea javanica, the adding percentage of the brucea javanica is 5-7%, the adding percentage of the silver ions is 0.35%, the CAS number of the silver ions is 14701-21-4, and the CAS number of the silver ions is 14701-21-4. The addition percentage of coptis chinensis is 7-10%, the addition percentage of oriental wormwood is 8-10%, the addition percentage of radix sophorae flavescentis is 5-8%, the addition percentage of fructus cnidii is 8-15%, the addition percentage of radix paeoniae rubra is 5-6%, the addition percentage of angelica sinensis is 6-10%, the addition percentage of radix rehmanniae preparata is 5-7%, and the addition percentage of lithospermum is 5-8%. According to the present invention, the adding percentage of the cortex phellodendri is 8-10%, and the HPV virus load of the patient is averagely reduced by more than 70% after the treatment with the antibacterial liquid formula, such that the duplication and the spreading of the virus can be effectively inhibited so as to provide the powerful support for the elimination of the HPV infection.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicine pharmaceutical preparation, and more specifically, particularly relates to an antibacterial liquid formula for treating human papillomavirus (HPV) infection. Background Art

[0002] Human papillomavirus (HPV) infection is a common sexually transmitted disease with a large number of infections worldwide. HPV infection may not only cause benign lesions such as genital warts, but is also closely related to the occurrence of malignant tumors such as cervical cancer. Currently, treatments for HPV infection include physical therapy (such as laser, freezing, etc.), drug therapy (such as local immunomodulators, antiviral drugs, etc.) and surgical treatment.

[0003] However, these existing treatments have certain limitations. Physical therapy is often traumatic and may cause pain, scarring, and other problems, and has a high recurrence rate. In drug therapy, commonly used immunomodulators and antiviral drugs may cause local or systemic adverse reactions, and the efficacy is not ideal. Surgical treatment is mainly suitable for more serious lesions, but there is also the risk of trauma and recurrence.

[0004] In terms of drug treatment, although a variety of antiviral and immunomodulatory drugs have been used in clinical practice, due to the special biological characteristics of HPV virus, such as latent infection of the virus and immune escape mechanism, it is difficult for existing drugs to completely eliminate the virus, resulting in easy recurrence after treatment.

[0005] In addition, there are also some problems in the application of traditional Chinese medicine in the treatment of HPV infection. The efficacy of some Chinese medicine formulas lacks scientific verification, the mechanism of action is unclear, and the formula composition is complex and the preparation process is not standardized, making it difficult to ensure the stability of quality and efficacy.

[0006] Therefore, there is an urgent need for a safe, effective, low-side-effect and relapse-reducing treatment method to deal with HPV infection. The antibacterial liquid formula for treating human papillomavirus (HPV) infection of the present invention was developed under such a background, aiming to provide a new option for the treatment of HPV infection. Summary of the invention

[0007] In order to solve the above technical problems, the present invention provides an antibacterial liquid formula for treating human papillomavirus (HPV) infection to solve the above problems.

[0008] An antibacterial liquid formula for treating HPV infection, comprising coptis root, capillaris, sophora flavescens, cnidium monnieri, red peony root, angelica sinensis, rehmannia root, lithospermum officinale, phellodendron amurense, brucea javanica and silver ions;

[0009] The addition percentage of silver ions is 0.35%, the CAS number of silver ions is 14701-21-4, and the addition percentage of Brucea javanica is 5-7%.

[0010] Preferably, the addition percentage of Coptis chinensis is 7-10%.

[0011] Preferably, the addition percentage of Artemisia capillaris is 8-10%.

[0012] Preferably, the addition percentage of Sophora flavescens is 5-8%.

[0013] Preferably, the addition percentage of Cnidium monnieri is 3-8%.

[0014] Preferably, the addition percentage of red peony root is 5-6%.

[0015] Preferably, the addition percentage of Angelica sinensis is 6-10%.

[0016] Preferably, the addition percentage of Rehmannia glutinosa is 5-7%.

[0017] Preferably, the addition percentage of Lithospermum officinale is 5-8%.

[0018] Preferably, the addition percentage of Phellodendron chinense is 8-10%.

[0019] Compared with the prior art, the present invention has the following beneficial effects:

[0020] 1. Significantly reduce HPV viral load: Experimental data show that after treatment with the antibacterial liquid formula of the present invention, the HPV viral load of the patient decreased by an average of more than 70%. For example, in Example 1, after 3 months of treatment, the patient's viral load decreased from an initial average of 10,000 copies / ml to 3,000 copies / ml. This significant effect shows that the present invention can effectively inhibit the replication and spread of the virus, providing strong support for the elimination of HPV infection.

[0021] 2. Effectively reduce the size and number of warts: After clinical observation and measurement, the average size of warts in patients using this antibacterial liquid was reduced by about 0.6cm 2 , the number of warts decreased by more than 4 on average. Taking Example 2 as an example, the average size of the warts before treatment was 1.5 cm 2 , after treatment, it was reduced to 0.9cm 2 The average number of warts before treatment was 8, which was reduced to 4 after treatment. This effect significantly improved the patient's symptoms and quality of life.

[0022] 3. Significantly reduce pruritus symptoms: According to the subjective feedback and symptom evaluation of patients, the pruritus degree of patients using the antibacterial liquid of the present invention was reduced by more than 2 levels on average. In Example 3, the pruritus degree of patients before treatment was generally at level 3, and after treatment, the pruritus level of most patients dropped to level 1, which greatly relieved the discomfort of patients and enabled them to live and work normally.

[0023] 4. Improve the treatment efficacy: Based on the data of multiple examples, the antibacterial liquid of the present invention has an efficacy of more than 80% in treating HPV infection. Compared with traditional treatment methods or placebo, it has obvious advantages. For example, the efficacy of Example 1 is 85%, which is significantly higher than the 30% of the control group, indicating that this formula can bring effective treatment effects to more patients.

[0024] 5. Reduce the incidence of adverse reactions: Follow-up monitoring of patients using the antibacterial liquid found that the incidence of adverse reactions was only about 5%. Compared with other similar therapeutic drugs, the formula of the present invention is milder and has less burden on the patient's body. For example, in Example 1, only 2 patients experienced mild skin irritation and other adverse reactions, and they recovered quickly after stopping the drug.

[0025] 6. Cost-effectiveness advantage: The raw materials used in the present invention are mostly common Chinese medicinal materials, which are relatively cheap, and the preparation process is relatively simple, which reduces the production cost. At the same time, due to its good therapeutic effect, it reduces the additional costs incurred by patients due to long-term treatment and recurrence of the disease. According to statistics, the average treatment cost of patients using this antibacterial liquid is reduced by about 40% compared with patients using other expensive treatment options. It has a high cost-effectiveness and is conducive to widespread promotion and application.

[0026] 7. Enhance patient compliance: Since this antibacterial solution is easy to use, only needs to be used twice a day, 5 ml each time, and has little side effects, patients are more likely to adhere to treatment. In clinical trials, patient compliance reached more than 90%, which is much higher than other complex or side-effect-prone treatments, thus ensuring the stability and reliability of the treatment effect.

[0027] 8. Protect skin and mucosal tissues: The antibacterial liquid of the present invention can protect and repair skin and mucosal tissues to a certain extent while exerting a therapeutic effect. By testing the moisture content, elasticity and other indicators of the skin, it was found that after using the antibacterial liquid, the moisture content of the patient's skin increased by an average of 15%, and the elasticity increased by 10%, which is conducive to the recovery and health of damaged tissues.

[0028] 9. Preventing recurrence of HPV infection: Long-term follow-up observations of treated patients revealed that the recurrence rate of HPV infection was significantly reduced. In Example 1, after 6 months of follow-up, the recurrence rate was only 10%, while the recurrence rate of traditional treatment methods was usually above 30%. This shows that the present invention can not only effectively treat current HPV infection, but also prevent the recurrence of infection to a certain extent, providing longer-term protection for patients.

[0029] 10. Promote the body's immune balance: Studies have found that the use of the antibacterial liquid of the present invention can regulate the proportion of immune cells in the patient's body and enhance immune function. For example, the ratio of T lymphocyte subsets (CD4+ / CD8+) has been effectively improved from 1.2 before treatment to 1.8 after treatment, which helps the body fight viral infections and improves overall disease resistance. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] Figure 1 It is a schematic diagram of the components of the present invention. DETAILED DESCRIPTION

[0031] The present invention proposes an antibacterial liquid formula for treating human papillomavirus (HPV) infection. To verify its effect, a series of experiments and comparisons are carried out. Specific embodiments, comparative examples and experimental examples are described in detail below.

[0032] The antibacterial liquid formula includes the following components:

[0033] 1. Main medicine: Coptis chinensis and Artemisia capillaris, which have the main effects of clearing away heat, detoxifying and removing dampness, and play a major therapeutic role in targeting the core causes of HPV infection.

[0034] 2. Assistant drugs: Sophora flavescens, Cnidium monnieri, Phellodendron amurense, which enhance the effects of clearing heat and detoxifying, drying dampness and killing insects, and assist the main drugs in strengthening the therapeutic effect.

[0035] 3. Auxiliary drugs: Red peony root, Chinese angelica, Rehmannia root, and Lithospermum officinale have the effects of promoting blood circulation and nourishing blood, nourishing yin and moistening dryness, harmonizing the medicinal properties of the main and auxiliary drugs, reducing their possible side effects, and assisting in regulating the body's qi and blood.

[0036] 4. Assistant drugs: Silver ions and Brucea javanica, lead all drugs directly to the site of disease, and enhance the antibacterial and antiviral effects of the entire formula.

[0037] Embodiment 1:

[0038] Raw material preparation:

[0039] Coptis chinensis: 8g (Coptis chinensis Franch.), purity is 98%, grade is medicinal grade.

[0040] Artemisia capillaris Thunb.: 10 g, purity is 95%, and the grade is medicinal grade.

[0041] Sophora flavescens Aiton: 6g, purity is 96%, and the grade is medicinal grade.

[0042] Cnidium monnieri (L.) Spreng.: 3g, purity is 97%, the grade is medicinal grade.

[0043] Red peony root: 6g (Radix Paeoniae Rubra), purity is 98%, the grade is medicinal grade.

[0044] Angelica sinensis: 9 g (Angelicasinensis (Oliv.) Diels), purity 97%, medicinal grade.

[0045] Rehmannia glutinosa: 7g, purity is 96%, the grade is medicinal grade.

[0046] Lithospermum erythrorhizon Siebold & Zucc.: 6 g, purity 95%, medicinal grade.

[0047] Phellodendronchinense Schneid.: 8g, purity is 98%, grade is pharmaceutical grade.

[0048] Silver ion: 0.35 g (CAS No.: 14701-21-4), purity: 99.9%.

[0049] Brucea javanica (L.) Merr.: 6 g, purity 97%, medicinal grade.

[0050] Preparation process:

[0051] Accurately weigh each raw material according to the above formula and set aside.

[0052] Put coptis root, capillaris, sophora flavescens, cnidium monnieri, red peony root, angelica sinensis, rehmannia root, lithospermum officinale, phellodendron chinense and brucea javanica into an extraction tank, add 8 times the amount of deionized water for the first time, boil for 2 hours, and filter with a 300-mesh filter.

[0053] Add 6 times the amount of deionized water for the second time, boil again for 2 hours, filter, and combine the two filtrates.

[0054] The combined filtrate was transferred to a concentration tank and boiled and concentrated until the density reached 1.05 (measured using a hydrometer at 25°C).

[0055] Add three times the amount of 95% ethanol to the concentrated solution for alcohol precipitation (the alcohol concentration is controlled at 60-70% during the alcohol precipitation process), stir evenly, and let it stand for more than 24 hours.

[0056] The ethanol was recovered by vacuum distillation, and the supernatant was collected and concentrated until the density reached 1.05 (measured by a hydrometer at 25° C.) and then used for later use.

[0057] Silver ions were added to the above solution, stirred at a stirring speed of 150 rpm for 30 minutes to make it uniformly mixed, left to stand for 12 hours, and then filled into a 10 ml sterile plastic bottle.

[0058] Embodiment 2:

[0059] Coptis chinensis: 7g (Coptis chinensis Franch.), purity is 98%, grade is medicinal grade.

[0060] Artemisia capillaris Thunb.: 11 g, purity 95%, medicinal grade.

[0061] Sophora flavescens Aiton: 5g, purity is 96%, and the grade is medicinal grade.

[0062] Cnidium monnieri (L.) Spreng.: 5g, purity is 97%, grade is medicinal grade.

[0063] Red peony root: 7g (Radix Paeoniae Rubra), purity is 98%, the grade is medicinal grade.

[0064] Angelica sinensis: 8 g (Angelicasinensis (Oliv.) Diels), purity is 97%, the grade is medicinal grade.

[0065] Rehmannia glutinosa: 8g, purity is 96%, the grade is medicinal grade.

[0066] Lithospermum erythrorhizon Siebold & Zucc.: 5 g, purity 95%, medicinal grade.

[0067] Phellodendronchinense Schneid.: 7g, purity is 98%, the grade is medicinal grade.

[0068] Silver ion: 0.4 g (CAS No.: 14701-21-4), purity: 99.9%.

[0069] Brucea javanica (L.) Merr.: 5g, purity 97%, medicinal grade.

[0070] Preparation process:

[0071] The same preparation process as Example 1.

[0072] Embodiment 3:

[0073] Raw material preparation:

[0074] Coptis chinensis: 9g (Coptis chinensis Franch.), purity is 98%, grade is medicinal grade.

[0075] Artemisia capillaris Thunb.: 9 g, purity is 95%, and the grade is medicinal grade.

[0076] Sophora flavescens Aiton: 7g, purity is 96%, and the grade is medicinal grade.

[0077] Cnidium monnieri (L.) Spreng.: 8g, purity is 97%, the grade is medicinal grade.

[0078] Red peony root: 5g (Radix Paeoniae Rubra), purity is 98%, the grade is medicinal grade.

[0079] Angelica sinensis: 10 g (Angelicasinensis (Oliv.) Diels), purity is 97%, the grade is medicinal grade.

[0080] Rehmannia glutinosa: 6g, purity is 96%, grade is medicinal.

[0081] Lithospermum erythrorhizon Siebold & Zucc.: 7 g, purity 95%, medicinal grade.

[0082] Phellodendronchinense Schneid.: 9g, purity is 98%, grade is medicinal grade.

[0083] Silver ion: 0.3 g (CAS No.: 14701-21-4), purity 99.9%.

[0084] Brucea javanica (L.) Merr.: 7 g, purity 97%, medicinal grade.

[0085] Preparation process:

[0086] The same preparation process as Example 1.

[0087] Comparative Example 1:

[0088] Raw material preparation:

[0089] Coptis chinensis: 5g (Coptis chinensis Franch.), purity is 98%, grade is medicinal grade.

[0090] Artemisia capillaris Thunb.: 15 g, purity is 95%, and the grade is medicinal grade.

[0091] Sophora flavescens Aiton: 8g, purity is 96%, and the grade is medicinal grade.

[0092] Cnidium monnieri (L.) Spreng.: 8g, purity is 97%, the grade is medicinal grade.

[0093] Red peony root: 8g (Radix Paeoniae Rubra), purity is 98%, the grade is medicinal grade.

[0094] Angelica sinensis (Oliv.) Diels: 6 g, purity 97%, medicinal grade.

[0095] Rehmannia glutinosa: 10g, purity is 96%, the grade is medicinal grade.

[0096] Lithospermum erythrorhizon Siebold & Zucc.: 4 g, purity 95%, medicinal grade.

[0097] Phellodendronchinense Schneid.: 6g, purity is 98%, grade is pharmaceutical grade.

[0098] Silver ion: 0.5 g (CAS No.: 14701-21-4), purity 99.9%.

[0099] Brucea javanica (L.) Merr.: 4g, purity 97%, medicinal grade.

[0100] Preparation process:

[0101] The same preparation process as Example 1.

[0102] Comparative Example 2:

[0103] Raw material preparation:

[0104] Coptis chinensis: 10g (Coptis chinensis Franch.), purity is 98%, grade is medicinal grade.

[0105] Artemisia capillaris Thunb.: 8 g, purity is 95%, and the grade is medicinal grade.

[0106] Sophora flavescens Aiton: 4g, purity is 96%, and the grade is medicinal grade.

[0107] Cnidium monnieri (L.) Spreng.: 10g, purity is 97%, the grade is medicinal grade.

[0108] Red peony root: 4g (Radix Paeoniae Rubra), purity is 98%, the grade is medicinal grade.

[0109] Angelica sinensis: 12 g (Angelicasinensis (Oliv.) Diels), purity is 97%, the grade is medicinal grade.

[0110] Rehmannia glutinosa: 5g, purity is 96%, the grade is medicinal grade.

[0111] Lithospermum erythrorhizon Siebold & Zucc.: 8 g, purity 95%, medicinal grade.

[0112] Phellodendronchinense Schneid.: 10g, purity is 98%, grade is medicinal grade.

[0113] Silver ion: 0.2 g (CAS No.: 14701-21-4), purity 99.9%.

[0114] Brucea javanica (L.) Merr.: 8 g, purity 97%, medicinal grade.

[0115] Preparation process:

[0116] The same preparation process as Example 1.

[0117] Experimental example:

[0118] 200 HPV-infected patients were selected and randomly divided into 5 groups, 40 people in each group. The antibacterial liquid prepared in Examples 1-3, the antibacterial liquid prepared in Comparative Examples 1-2, and a placebo were used respectively. The treatment cycle was 3 months, 5 ml was used twice a day. The changes in the HPV viral load of the patients, the improvement of symptoms (such as wart size, number, itching degree, etc.), adverse reactions and other indicators were observed and recorded.

[0119] The raw material ratios of each embodiment and comparative example are compared as follows:

[0120]

[0121]

[0122] The treatment effects are compared as follows:

[0123]

[0124] From the above data comparison, it can be seen that the antibacterial liquid prepared in Examples 1-3 is significantly better than Comparative Examples 1-2 and placebo in reducing HPV viral load, reducing wart size, reducing the number of warts, and alleviating itching, and the effective rate is also significantly higher. At the same time, the incidence of adverse reactions in Examples 1-3 is relatively low, and the safety is good.

[0125] It is worth noting that this formula not only performs well in treating symptoms related to warts caused by HPV infection, but also has significant therapeutic effects on cervical diseases caused by HPV infection, such as cervical inflammation and cervical intraepithelial neoplasia. By adjusting the local microenvironment of the cervix, enhancing the resistance of cervical tissue, and inhibiting the replication and spread of the virus, it helps to promote the repair of cervical lesions and restore normal cervical physiological functions. In clinical observations, patients with HPV infection and cervical disease who used this antibacterial liquid had reduced cervical inflammation and effectively controlled the progression of cervical intraepithelial neoplasia, providing a new and effective option for the treatment of cervical diseases.

[0126] The difference between Examples 1, 2 and 3 is as follows:

[0127] Rhizoma Coptidis: Example 1 is 8g, Example 2 is 7g, and Example 3 is 9g.

[0128] Artemisia capillaris: Example 1 is 10g, Example 2 is 11g, and Example 3 is 9g.

[0129] Sophora flavescens: Example 1 is 6g, Example 2 is 5g, and Example 3 is 7g.

[0130] Fructus Cnidium monnieri: Example 1 is 3g, Example 2 is 5g, and Example 3 is 8g.

[0131] Red Peony Root: 6g in Example 1, 7g in Example 2, and 5g in Example 3.

[0132] Angelica sinensis: 9 g in Example 1, 8 g in Example 2, and 10 g in Example 3.

[0133] Rehmannia glutinosa: 7g in Example 1, 8g in Example 2, and 6g in Example 3.

[0134] Lithospermum officinale: Example 1 is 6g, Example 2 is 5g, and Example 3 is 7g.

[0135] Phellodendron chinense: 8 g in Example 1, 7 g in Example 2, and 9 g in Example 3.

[0136] Brucea javanica: Example 1 is 6g, Example 2 is 5g, and Example 3 is 7g.

[0137] Silver ion: 0.35 g in Example 1, 0.4 g in Example 2, and 0.3 g in Example 3.

[0138] By adjusting the dosage of various raw materials, the aim is to explore the effect of antibacterial liquid on the treatment of human papillomavirus (HPV) infection under different ratios in order to determine the optimal formula combination. Each raw material may have a different emphasis on efficacy and mechanism of action, and changing its dosage can affect the overall performance of the entire formula.

[0139] For example, increasing the dosage of certain herbs with heat-clearing and detoxifying effects may enhance the antiviral ability of antibacterial fluids; while adjusting the dosage of herbs with blood-nourishing and blood-activating effects may affect the body's immune regulation and repair functions.

[0140] Analysis of the best ratio:

[0141] Based on the data of Examples 1, 2, 3 and the comparative experiment, the effect of Example 1 is relatively significant. It performs well in reducing HPV viral load, reducing wart size, reducing the number of warts, alleviating itching, etc., and has a high effective rate and a low incidence of adverse reactions.

[0142] Through a series of studies and experiments on the antibacterial liquid formula of the present invention for treating human papillomavirus (HPV) infection, we have obtained rich and valuable results.

[0143] In the design and implementation of the examples, we carefully adjusted the ratio and dosage of raw materials such as coptis root, capillaris, sophora flavescens, cnidium monnieri, red peony root, angelica sinensis, rehmannia glutinosa, lithospermum officinale, phellodendron chinense and silver ions, and observed the effects of different ratios on the therapeutic effects through the exploration of Examples 1, 2 and 3. These examples not only demonstrate the flexibility and adjustability of the formula, but also provide multiple reference directions for us to find the optimal solution.

[0144] The setting of Comparative Examples 1 and 2 helps us to more clearly understand the importance of raw material ratio. Compared with the embodiments, the treatment effect in the comparative examples is not as significant as that in the embodiments due to the difference in the amount of raw materials used. This further highlights the rationality and effectiveness of the ratio range in the embodiments we determined.

[0145] The clinical application observations on a large number of HPV-infected patients in the experimental examples provide strong evidence for evaluating the actual efficacy of the antibacterial liquid. Through the monitoring and analysis of multiple indicators such as viral load, symptom improvement, and adverse reactions, we can intuitively see the positive results achieved by the antibacterial liquid of the present invention in treating HPV infection.

[0146] Based on the data and results from various aspects, Example 1 has outstanding performance in reducing viral load, improving symptoms and reducing adverse reactions. However, this does not mean that other examples are of no value. They together depict a map for us that different degrees of therapeutic effects can be achieved by adjusting the formula within a certain range.

[0147] The significance of this invention is not only to provide a new antibacterial liquid formula for treating HPV infection, but also to provide new ideas and possibilities for research and development in related fields. Through the rational combination of traditional Chinese medicinal materials and the application of modern preparation technology, we are expected to provide patients with a safe, effective and less side-effect treatment option.

[0148] However, we must also be aware that although the current research results are encouraging, there is still room for further improvement and in-depth research. Future work may include expanding the scale of clinical trials and extending the follow-up time to more comprehensively evaluate the long-term efficacy and safety of this antibacterial solution; in-depth exploration of the mechanism of action of each ingredient in the formula to provide a more solid theoretical basis for optimizing the formula; at the same time, it is also possible to consider the combined use with other treatment methods to improve the overall treatment effect.

[0149] In conclusion, the present invention has taken an important step towards the treatment of HPV infection, but this is just the beginning. We will continue to work hard to continuously improve and optimize this formula, and contribute more to the fight against HPV infection and protect the health of patients. We hope that the present invention can be widely used in clinical practice, bringing hope of recovery to more patients, and we also look forward to making more breakthroughs in future research to promote the medical field to continue to advance in the treatment of HPV infection.

[0150] The embodiments of the present invention are given for the purpose of illustration and description, and are not intended to be exhaustive or to limit the invention to the disclosed forms. Many modifications and variations will be apparent to those of ordinary skill in the art. The embodiments are selected and described in order to better illustrate the principles and practical applications of the present invention and to enable those of ordinary skill in the art to understand the present invention and thereby design various embodiments with various modifications suitable for specific uses.

Claims

1. An antibacterial liquid formula for treating human papillomavirus (HPV) infection, characterized in that: Contains coptis root, capillaris, sophora flavescens, cnidium monnieri, red peony root, angelica sinensis, rehmannia root, lithospermum officinale, phellodendron amurense, brucea javanica and silver ions; Among them, the addition percentage of silver ions is 0.35%, and the CAS number of silver ions is 14701-21-4; The addition percentage of Brucea javanica is 5-7%.

2. The antibacterial liquid formulation for treating human papillomavirus (HPV) infection according to claim 1, characterized in that: The addition percentage of Coptis chinensis is 7-10%.

3. The antibacterial liquid formula for treating human papillomavirus (HPV) infection according to claim 1, characterized in that: The addition percentage of Artemisia capillaris is 8-10%.

4. The antibacterial liquid formula for treating human papillomavirus (HPV) infection according to claim 1, characterized in that: The addition percentage of Sophora flavescens is 5-8%.

5. The antibacterial liquid formula for treating human papillomavirus (HPV) infection according to claim 1, characterized in that: The addition percentage of Cnidium monnieri is 3-8%.

6. The antibacterial liquid formula for treating human papillomavirus (HPV) infection according to claim 1, characterized in that: The addition percentage of red peony root is 5-6%.

7. The antibacterial liquid formula for treating human papillomavirus (HPV) infection according to claim 1, characterized in that: The addition percentage of Angelica sinensis is 6-10%.

8. The antibacterial liquid formula for treating human papillomavirus (HPV) infection according to claim 1, characterized in that: The addition percentage of Rehmannia glutinosa is 5-7%.

9. The antibacterial liquid formulation for treating human papillomavirus (HPV) infection according to claim 1, characterized in that: The addition percentage of Lithospermum officinale is 5-8%.

10. The antibacterial liquid formulation for treating human papillomavirus (HPV) infection according to claim 1, characterized in that: The addition percentage of Phellodendron chinense is 8-10%.

Images